TiGenix Cx601 positive Phase III results to be presented at Digestive Disease Week in the USA
LEUVEN, Belgium, May 18, 2016 (GLOBE NEWSWIRE) -- TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, is …